Atherosclerotic cardiovascular disease risk and evidence-based management of cholesterol

North American Journal of Medical Sciences

Volumn 6, Issue 5, 2014, Pages 191-198

  Roy, Satyajeet ^a  

^a Division of Female Pelvic Medicine and Reconstructive Surgery   (United States)

Author keywords

Atherosclerotic cardiovascular disease; Cholesterol management; Statin

Indexed keywords

ALANINE AMINOTRANSFERASE; ATORVASTATIN; C REACTIVE PROTEIN; CREATINE KINASE; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PITAVASTATIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

AGATSTON SCORE; ANKLE BRACHIAL INDEX; ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DIABETES MELLITUS; DRUG THERAPY; EVIDENCE BASED MEDICINE; GOVERNMENT; HEMODIALYSIS PATIENT; HIGH INTENSITY STATIN THERAPY; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; LIFESTYLE MODIFICATION; MEDICAL RECORD REVIEW; META ANALYSIS (TOPIC); MODERATE INTENSITY STATIN THERAPY; NATIONAL HEALTH ORGANIZATION; NEW YORK HEART ASSOCIATION CLASS; PATIENT DECISION MAKING; PATIENT PREFERENCE; PRACTICE GUIDELINE; PUBLIC HEALTH SERVICE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK REDUCTION; UNITED STATES;

EID: 84901367416     PISSN: 22501541     EISSN: 19472714     Source Type: Journal    
DOI: 10.4103/1947-2714.132916     Document Type: Review

References (64)

1. Prevalence of cholesterol screening and high blood cholesterol among adults-United States, 2005, 2007, and 2009. Centers for Disease Control and Prevention. Atlanta, GA.: Morbidity and Mortality Weekly Report, 2012. (Accessed March 20, 2014, at http://www.cdc.gov/mmwr/preview/mmwrhtml/ mm6135a2.htm).
2. Chronic Conditions among Medicare Benefi ciaries. Centers for Medicare and Medicaid Services. Baltimore, MD.: Chartbook, 2012. (Accessed March 20, 2014, at http://www.cms.gov/ Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/Chronic-Conditions/Downloads/2012Chartbook. pdf).
3. Stone NJ, Robinson J, Lichtenstein AH, Bairey Merz CN, Lloyd-Jones DM, Blum CB, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: A report of the American College of Cardiology-American Heart Association Task Force on Practice Guidelines. Circulation 2013 [In Press].
4. Vital signs: Prevalence, treatment, and control of high levels of low-density lipoprotein Cholesterol, United States, 1999-2002 and 2005-2008. Centers for Disease Control and Prevention. Atlanta, GA.: Morbidity and Mortality Weekly Report, 2011. (Accessed March 20, 2014, at http://www.cdc.gov/mmwr/ preview/mmwrhtml/mm6004a5.htm).
5. Screening for Lipid Disorders in Adults. United States Preventive Services Task Force. Rockville, MD.: U.S. Preventive Services Task Force Recommendation Statement; 2008. (Accessed March 20, 2014, at http://www. uspreventiveservicestaskforce.org/uspstf08/lipid/lipidrs. htm).
6. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) fi nal report. Circulation 2002;106:3143-421.
7. Gibbons GH, Shurin SB, Mensah GA, Lauer MS. Refocusing the agenda on cardiovascular guidelines: An announcement from the national heart, lung, and blood institute. Circulation 2013;128:1713-5.
8. Clinical Practice Guidelines We Can Trust-Committee on Standards for Developing Trustworthy Clinical Practice Guidelines. In: Graham R, Mancher M, Miller Wolman D, Greenfi eld S, Steinberg E, editors. Institute of Medicine of the National Academics. Washington, DC: The National Academies Press; 2011. p. 1-254.
9. Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
10. CV risk calculator. American Heart Association. Dallas, TX.: Prevention Guidelines Tools, 2013. (Accessed March 20, 2014, at http://my.americanheart.org/cvriskcalculator).
11. Eckel RH, Jakicic JM, Ard JD, Miller NH, Hubbard VS, Nonas CA, et al. 2013 AHA-ACC Guideline on Lifestyle Management to Reduce Cardiovascular Risk: A Report of the American College of Cardiology-American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013; pii:S0735-1097.
12. Cholesterol Treatment Trialists Collaboration, Mihaylova B, Emberson J, Blackwell L, Keech A, Simes J, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: Meta-analysis of individual data from 27 randomised trials. Lancet 2012;380:581-90.
13. AIM-HIGH Investigators, Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011;365:2255-67.
14. ACCORD Study Group, Ginsberg HN, Elam MB, Lovato LC, Crouse JR 3rd, Leiter LA, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010;362:1563-74.
15. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. Air Force/ Texas Coronary Atherosclerosis Prevention Study. JAMA 1998;279:1615-22.
16. Nakamura H, Arakawa K, Itakura H, Kitabatake A, Goto Y, Toyota T, et al. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): A prospective randomised controlled trial. Lancet 2006;368:1155-63.
17. Taylor F, Ward K, Moore TH, Burke M, Davey Smith G, Casas JP, et al. Statins for the primary prevention of cardiovascular disease. The Cochrane Collaboration. Oxford, UK: Cochrane database of systematic reviews; 2011. (Accessed March 20, 2014, at http://www.onlinelibrary.wiley.com/ doi/10.1002/14651858.CD004816.pub4/abstract).
18. Cholesterol Treatment Trialists Collaboration. Effi cacy and safety of more intensive lowering of LDL cholesterol: A metaanalysis of data from 170,000 participants in 26 randomised trials. Lancet 2010;376:1670-81.
19. Taylor F, Huffman MD, Macedo AF, Moore TH, Burke M, Davy Smith G, et al. Statins for the primary prevention of cardiovascular disease. The Cochrane Collaboration. Oxford, UK.: Cochrane database of systematic reviews, 2011. (Accessed March 20, 2014, at http://www.onlinelibrary. wiley.com/doi/10.1002/14651858.CD004816.pub5/abstract).
20. Heart Protection Study Collaborative Group. MRC/ BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet 2002;360:7-22.
21. Lu Z, Kou W, Du B, Wu Y, Zhao S, Brusco OA, et al. Effect of Xuezhikang, an extract from red yeast Chinese rice, on coronary events in a Chinese population with previous myocardial infarction. Am J Cardiol 2008;101:1689-93.
22. Tikkanen MJ, Holme I, Cater NB, Szarek M, Faergeman O, Kastelein JJ, et al. Comparison of effi cacy and safety of atorvastatin (80 mg) to simvastatin (20 to 40 mg) in patients aged <65 versus >or=65 years with coronary heart disease (from the Incremental DEcrease through Aggressive Lipid Lowering [IDEAL] study). Am J Cardiol 2009;103:577-82.
23. Holmes HM, Hayley DC, Alexander GC, Sachs GA. Reconsidering medication appropriateness for patients late in life. Arch Intern Med 2006;166:605-9.
24. Akushevich I, Kravchenko J, Ukraintseva S, Arbeev K, Yashin AI. Age patterns of incidence of geriatric disease in the U.S. elderly population: Medicare-based analysis. J Am Geriatr Soc 2012;60:323-7.
25. Robinson JG, Bakris G, Torner J, Stone NJ, Wallace R. Is it time for a cardiovascular primary prevention trial in the elderly? Stroke 2007;38:441-50.
26. Porock D, Oliver DP, Zweig S, Rantz M, Mehr D, Madsen R, et al. Predicting death in the nursing home: Development and validation of the 6-month Minimum Data Set mortality risk index. J Gerontol A Biol Sci Med Sci 2005;60:491-8.
27. Stineman MG, Xie D, Pan Q, Kurichi JE, Zhang Z, Saliba D, et al. All-cause 1-, 5-, and 10-year mortality in elderly people according to activities of daily living stage. J Am Geriatr Soc 2012;60:485-92.
28. Fried T, Bradley E, Towle V, Allore H. Understanding the treatment preferences of seriously ill patients. N Engl J Med 2002;346:1061-6.
29. Ditto PH, Druley JA, Moore KA, Danks JH, Smucker WD. Fates worse than death: The role of valued life activities in health-state evaluations. Health Psychol 1996;15:332-43.
30. Rosenfeld K, Wenger N, Kagawa-Singer M. End-of-life decision making: A qualitative study of elderly individuals. J Gen Intern Med 2000;15:620-5.
31. Glynn RJ, Koenig W, Nordestgaard BG, Shepherd J, Ridker PM. Rosuvastatin for primary prevention in older persons with elevated C-reactive protein and low to average lowdensity lipoprotein cholesterol levels: Exploratory analysis of a randomized trial. Ann Intern Med 2010;152:488-96.
32. Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): A randomised controlled trial. Lancet 2002;360:1623-30.
33. Schonberg MA, Davis RB, McCarthy EP, Marcantonio ER. External validation of an index to predict up to 9-year mortality of community-dwelling adults aged 65 and older. J Am Geriatr Soc 2011;59:1444-51.
34. Fried TR, Tinetti ME, Iannone L, O'Leary JR, Towle V, Van Ness PH. Health outcome prioritization as a tool for decision making among older persons with multiple chronic conditions. Arch Intern Med 2011;171:1854-6.
35. Barry MJ, Edgman-Levitan S. Shared decision making-The pinnacle of patient-centered care. N Engl J Med 2012;366:780-1.
36. Man-Son-Hing M, Gage BF, Montgomery AA, Howitt A, Thomson R, Devereaux PJ, et al. Preference-based antithrombotic therapy in atrial fi brillation: Implications for clinical decision making. Med Decis Making 2005;25:548-59.
37. Gray SL, Boudreau RM, Newman AB, Studenski SA, Shorr RI, Bauer DC, et al. Angiotensin-converting enzyme inhibitor and statin use and incident mobility limitation in community-dwelling older adults: The Health, Aging and Body Composition Study. J Am Geriatr Soc 2011;59:2226-32.
38. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359:2195-207.
39. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): Multicentre randomised placebo-controlled trial. Lancet 2004;364:685-96.
40. Pedersen TR, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, Holme I, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: The IDEAL study: A randomized controlled trial. JAMA 2005;294:2437-45.
41. Berglund L, Brunzell JD, Goldberg AC, Goldberg IJ, Sacks F, Murad MH, et al. Evaluation and treatment of hypertriglyceridemia: An endocrine society clinical practice guideline. J Clin Endocrinol Metab 2012;97:2969-89.
42. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Effi cacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-78.
43. Rhodes ET, Prosser LA, Hoerger TJ, Lieu T, Ludwig DS, Laffel LM. Estimated morbidity and mortality in adolescents and young adults diagnosed with type 2 diabetes mellitus. Diabet Med 2012;29:453-63.
44. Nease RF Jr, Kneeland T, O'Connor GT, Sumner W, Lumpkins C, Shaw L, et al. Ischemic Heart Disease Patient Outcomes Research Team. Variation in patient utilities for outcomes of the management of chronic stable angina: Implications for clinical practice guidelines. JAMA 1995;273:1185-90.
45. Hippisley-Cox J, Pringle M, Cater R, Coupland C, Meal A. Coronary heart disease prevention and age inequalities: The fi rst year of the National Service Framework for CHD. Br J Gen Pract 2005;55:369-75.
46. Forman DE, Rich MW, Alexander KP, Zieman S, Maurer MS, Najjar SS, et al. Cardiac care for older adults: Time for a new paradigm. J Am Coll Cardiol 2011;57:1801-10.
47. Paynter NP, Mazer NA, Pradhan AD, Gaziano JM, Ridker PM, Cook NR. Cardiovascular risk prediction in diabetic men and women using hemoglobin A1c vs diabetes as a high-risk equivalent. Arch Intern Med 2011;171:1712-8.
48. Vodnala D, Rubenfire M, Brook RD. Secondary causes of dyslipidemia. Am J Cardiol 2012;110:823-5.
49. Fellström BC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, Beutler J, et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 2009;360:1395-407.
50. GISSI-HF Investigators, Tavazzi L, Maggioni AP, Marchioli R, Barlera S, Franzosi MG, et al. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): A randomised, double-blind, placebo-controlled trial. Lancet 2008;372:1231-9.
51. Kjekshus J, Apetrei E, Barrios V, Böhm M, Cleland JG, Cornel JH, et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007;357:2248-61.
52. Ridker PM, Cook NR. Statins: New American guidelines for prevention of cardiovascular disease. Lancet 2013;382:1762-5.
53. Keaney JF Jr, Curfman GD, Jarco JA. A Pragmatic View of the New Cholesterol Treatment Guidelines. N Engl J Med 2014;370:275-8.
54. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333:1301-7.
55. Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfield M, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): A multicentre randomised controlled trial. Lancet 2003;361:1149-58.
56. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005;352:1425-35.
57. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495-504.
58. Thompson GR, Packard CJ, Stone NJ. Goals of statin therapy: Three viewpoints. Curr Atheroscler Rep 2002;4:26-33.
59. Roffi M, Angiolillo DJ, Kappetein AP. Current concepts on coronary revascularization in diabetic patients. Eur Heart J 2011;32:2748-57.
60. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005;353:2643-53.
61. Miller M, Stone NJ, Ballantyne C, Bittner V, Criqui MH, Ginsberg HN, et al. Triglycerides and cardiovascular disease: A scientifi c statement from the American Heart Association. Circulation 2011;123:2292-333.
62. American Diabetes Association. Standards of medical care in diabetes-2013. Diabetes Care 2013;36:S11-66.
63. Martin SS, Blaha MJ, Elshazly MB, Toth PP, Kwiterovich PO, Blumenthal RS, et al. Comparison of a novel method vs the Friedewald equation for estimating low-density lipoprotein cholesterol levels from the standard lipid profi le. JAMA 2013;310:2061-8.
64. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.